Navigation Links
Cynosure Reports First-Quarter 2013 Financial Results
Date:4/30/2013

alification under the securities laws of any such jurisdiction.  No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

 Consolidated Statements of Income (Unaudited)(In thousands, except per share data)Three Months Ended March 31,20132012Revenues$
40,690

$
34,168Cost of revenues 17,003

14,660Gross profit23,687

19,508Operating expensesSelling and marketing 

12,603

11,551Research and development3,781

3,239Amortization of intangible assets acquired

214

342General and administrative 

5,101

3,518Total operating expenses21,699

18,650Income from operations1,988

858Interest income, net

32

10Other (expense) income, net

(357)

209Income before income taxes1,663

1,077Income tax provision 

424

258Net income$
,239

$
819Diluted net income per share 

$
.07

$
.06Diluted weighted average shares outstanding

16,860

13,037Basic net income per share 

$
.08

$
.07Basic weighted average shares outstanding

16,185

12,578 

 Condensed Consolidated Balance Sheet (In thousands)March 31, December 31, 20132012(Unaudited)Assets:Cash, cash equivalents and marketable securities

$
89,237$
86,057Short-term investments and related financial instruments

43,77040,617Accounts receivable, net20,94517,970Inventories32,86632,906Deferred tax asset, current portion779783Prepaid expenses and other current assets5,0755,149Total current assets192,672183,482Property and equipment, net8,6888,207Long-term marketable securities13,63720,071Goodwill and intangibles, net21,37621,748Other noncurrent assets1,0161,061Total assets$
237,389$
234
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
2. Cynosure Announces Upcoming Conference Presentations
3. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
4. Cynosure, Inc. Prices Public Offering of Class A Common Stock
5. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
6. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 12
7. Cynosure to Participate in Leerink Swann Global Healthcare Conference 2013
8. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
9. Cynosure Announces Presentation of 16 Abstracts at 33rd ASLMS Annual Conference
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 1, 2014   Intarcia Therapeutics, Inc. today ... phase 3 clinical trials for ITCA 650 (exenatide, delivered ... osmotic mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, ... and safety of ITCA 650 in patients with type ... to be significantly superior to placebo for both 40 ...
(Date:10/1/2014)... 1, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technology used to develop and produce enzymes ... biopharmaceuticals, and industrial enzymes industries, today announced the ... Bioenergy for commercial scale production of Abengoa,s proprietary ... developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3NeuroCall Awarded Joint Commission Accreditation 2
... Ltd. (NYSE Amex: CPD ) announced that ... (Sun) have been extended until January 28, 2012 but ... which was originally set to expire in January 2010, ... and is being extended for an additional 1 year ...
... Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its ... with the Securities and Exchange Commission.  As a result, the ... 2010 Form 10-K to enable its securities to continue trading ... is currently working on preparing and filing its quarterly reports ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 2Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 2K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 4K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 6K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 7K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 8
(Date:10/2/2014)... Dennis Thompson HealthDay ... -- Hospitals that pull out all the stops to ... saving lives, but the cost of such heroism is ... are about 5 percent better at saving elderly patients ... that operate with less intensity, said senior author Dr. ...
(Date:10/2/2014)... by scientists at The University of Nottingham could lead ... painkiller. , A drug resulting from the research, published ... offer new hope to sufferers of chronic pain conditions ... painkillers are currently available. , The work, led by ... Sciences, in collaboration with David Bates, Professor of Oncology ...
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... in the Journal of the American Medical Association ... with moderate or severe chronic knee pain, acupuncture did ... of Melbourne randomly assigned 282 patients (50 years or ... sham or pretend laser treatment. , Treatments were ... to laser and sham (inactive) laser acupuncture. , Researcher ...
(Date:10/1/2014)... and Physical Sciences Research Council (EPSRC) will focus ... control systems which run, for example, manufacturing plants, ... network. , The research will help understand ... the systems behind our critical national infrastructure. ... Systems (RITICS), based at Imperial College London, is ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Medical discovery first step on path to new painkillers 2Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2
... By studying the addition of sugars to proteins ... nervous system of insects, Karen Palter, researcher of ... to better understand neurodegenerative diseases in humans. Currently, ... projects exploring the glycosylation process that could eventually ...
... has increased in recent years, the Washington Post reports. ... and the American Society of Aesthetic Plastic Surgery, while ... medicine procedures, the number of blacks, Hispanics and Asians ... five years. In 2002, minorities accounted for 16% of ...
... Evidence is accumulating that depression is a risk factor ... Women's Health Watch. A recent study found that ... called selective serotonin reuptake inhibitors (SSRIs) had double the ... Other research points to depression itself as a source ...
... development and spread of drug-resistant tuberculosis (TB), the Stop TB ... Global Drug Facility, has provided anti-TB drug treatments for 10 ... ,"This is an important milestone, because getting anti-TB ... complete their treatment is the only way to break the ...
... the myriad strains of the human immunodeficiency virus (HIV) ... conducted at the Uniformed Services University of the Health ... variable, its prevention requires a vaccine effective enough to ... neutralise multiple viral strains. ,The latest ...
... Girls actress Lindsay Lohans father, Michael, believes now that his ... change her life completely. ,Lohan is currently ... in Malibu. ,Michael believes that Lohan can ... negative influence. ,"I'm glad she's there and ...
Cached Medicine News:Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 3Health News:Stop TB Partnership Has Provided Treatments for Ten Million People in Six Years 2
Small pupil irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip and front notch, for engaging the iris, 0.6 mm dual sideports, 20 gauge....
Irrigating nucleus chopper, 0.6 mm dual sideports, 20 gauge. For the right handed surgeon....
Karate phaco chopper, semi-sharp, wedge shaped inferior edge with a pointed tip...
Phaco chopper, short (0.75 mm) pointed "quick chop" tip....
Medicine Products: